AKBA — Akebia Therapeutics, Inc.

Summary of Akebia Therapeutics, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: Total revenues were $57.6 million, up from $46.5 million in Q4 2024.
• Full Year 2025 Revenue: Total revenues reached $236.2 million, compared to $160.2 million in 2024.
• Vafseo Revenue: Generated $6.2 million in Q4 2025 and $45.8 million for the full year.
• Auryxia Revenue: Reported $48.1 million in Q4 2025, up from $44.4 million in Q4 2024, and $181.5 million for the year.
• Net Loss: Decreased to $12.2 million in Q4 2025 from $22.8 million in Q4 2024; full-year net loss was $5.3 million, down from $69.4 million in 2024.
• Cash Position: Cash and cash equivalents stood at $184.8 million as of December 31, 2025, compared to $51.9 million a year prior.

2. Strategic Updates and Business Highlights

• Vafseo Launch: The oral HIF-PH inhibitor for treating anemia in chronic kidney disease saw a strong start, with over 1,000 prescribers and access for 290,000 patients in dialysis clinics.
• Clinical Data: Positive data from the ASN meeting indicated Vafseo's potential to reduce hospitalization and costs compared to existing treatments.
• Pipeline Expansion: Introduction of a rare kidney disease pipeline, including praliciguat and AKB-097, with plans for clinical trials in 2026 and beyond.
• R&D Day: Scheduled for April 2, 2026, to discuss mid-stage assets and provide deeper insights into the pipeline.

3. Forward Guidance and Outlook

• 2026 Expectations: Management expressed optimism for growth in Vafseo sales, although they refrained from providing specific revenue guidance.
• Clinical Trials: Anticipated results from the VOCAL study in Q4 2026 and the VOICE trial in early 2027, which are expected to support Vafseo's adoption as standard care.
• Adherence Improvement: Noted improvements in patient adherence rates, particularly with the implementation of observed dosing protocols.

4. Bad News, Challenges, or Points of Concern

• Demand Fluctuations: Vafseo demand was slightly down in Q4 2025 due to a transition to observed dosing protocols at dialysis organizations, leading to a one-time inventory drawdown of $4.8 million.
• Competitive Pressures: Anticipation of increased generic competition for Auryxia, which may impact revenue in 2026.
• Adoption Pace: The slower-than-expected adoption of Vafseo by dialysis providers was highlighted as a challenge, with management noting that nephrologists tend to adopt new treatments more cautiously.

5. Notable Q&A Insights

• Growth Expectations: Management emphasized that while they expect growth in Vafseo sales, they are cautious about projecting specific revenue figures due to the complexities of the dialysis market.
• Data Impact: The importance of upcoming clinical data (from VOCAL and VOICE studies) in influencing physician adoption and utilization of Vafseo was discussed.
• AKB-097 Protocol: Updates on the IND for AKB-097 indicated that the protocol is being simplified for easier recruitment, with plans to resubmit soon.
• Education Efforts: Increased focus on educating anemia managers and nephrologists about Vafseo's benefits was noted as crucial for driving adoption.

Overall, Akebia Therapeutics demonstrated solid financial growth in 2025, with strategic initiatives aimed at enhancing the adoption of Vafseo and expanding its pipeline. However, challenges in demand fluctuations and competitive pressures remain key concerns for the company moving forward.